Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
NCT ID: NCT05464823
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
111 participants
INTERVENTIONAL
2022-07-07
2027-05-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
NCT06557330
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
NCT00991211
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
NCT00864942
Home Hospital for Lymphoma
NCT04423848
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
NCT02856646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• To determine the feasibility and turnaround of clinical WES and transcriptome sequencing
Secondary Objectives:
* To determine the frequency of actionable DNA and RNA alterations
* To determine the concordance of DNA and RNA alterations
* To determine the frequency of molecularly matched therapy
* To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
* To determine the feasibility of molecularly matched therapy to acquired resistance alterations
Exploratory Objectives:
* To determine the feasibility of prioritizing targets with precision analytics
* To determine clinical outcomes in patients receiving molecularly matched therapy
* To determine the role of additional emerging diagnostic technologies
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Molecular Testing
Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Molecular Functional Portrait
Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Molecular Functional Portrait
Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
3. Provision of written informed consent for the study.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Westin, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
M D Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2022-05783
Identifier Type: OTHER
Identifier Source: secondary_id
2022-0396
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.